Literature DB >> 22308870

Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant.

Zeynep Siklar1, Sian Ellard, Emel Okulu, Merih Berberoğlu, Elizabeth Young, Senay Savaş Erdeve, Ilke Akin Mungan, Bülent Hacihamdioğlu, Omer Erdeve, Saadet Arsan, Gönül Oçal.   

Abstract

Neonatal diabetes mellitus (NDM) is a rare condition that can be either transient or permanent. K(ATP) channel (Kir6.2 or SUR1) mutation, chromosome 6 abnormalities, insulin, or glucokinase gene mutations can lead to isolated NDM. Cases caused by Kir6.2 mutation usually result in permanent NDM (PNDM) rather than transient NDM (TNDM). The majority of patients with the Kir6.2 or SUR1 mutation can be successfully managed with a sulfonylurea agent, without the need for insulin. We report a preterm male with NDM having two novel missense mutations, E322A and D352H, in the KCNJ11 gene. At 2 months of age, successful transition from insulin to glibenclamide (glyburide) therapy of the patient was managed. At 5 months of age, his diabetes went in to remission.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22308870     DOI: 10.1515/jpem.2011.250

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  6 in total

Review 1.  Personalized medicine in diabetes mellitus: current opportunities and future prospects.

Authors:  Jeffrey W Kleinberger; Toni I Pollin
Journal:  Ann N Y Acad Sci       Date:  2015-04-23       Impact factor: 5.691

Review 2.  Pharmacogenetic studies update in type 2 diabetes mellitus.

Authors:  Shalini Singh; Kauser Usman; Monisha Banerjee
Journal:  World J Diabetes       Date:  2016-08-10

3.  KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.

Authors:  Jingwen Song; Yunzhong Yang; Franck Mauvais-Jarvis; Yu-Ping Wang; Tianhua Niu
Journal:  BMC Med Genet       Date:  2017-06-06       Impact factor: 2.103

Review 4.  New insights into KATP channel gene mutations and neonatal diabetes mellitus.

Authors:  Tanadet Pipatpolkai; Samuel Usher; Phillip J Stansfeld; Frances M Ashcroft
Journal:  Nat Rev Endocrinol       Date:  2020-05-06       Impact factor: 43.330

5.  Changing the Treatment of Permanent Neonatal Diabetes Mellitus from Insulin to Glibenclamide in a 4-Month-Old Infant with KCNJ11 Activating Mutation.

Authors:  Homa Ilkhanipoor; Zohreh Karamizadeh
Journal:  Int J Prev Med       Date:  2013-09

Review 6.  Pharmacogenetics and personalized treatment of type 2 diabetes.

Authors:  Sabina Semiz; Tanja Dujic; Adlija Causevic
Journal:  Biochem Med (Zagreb)       Date:  2013       Impact factor: 2.313

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.